Pharmaceutical Benefits Advisory Committee

Last updated: 13.02.2014




Company description

The Pharmaceutical Benefits Advisory Committee is an independent statutory body established on 12 May 1954 under section 101 of the National Health Act 1953 to make recommendations and give advice to the Minister about which drugs and medicinal preparations should be made available as pharmaceutical benefits. No new vaccines may be made available through the National Immunisation Program or Pharmaceutical Benefits Scheme unless the Committee has so recommended

The Pharmaceutical Benefits Advisory Committee is required by the Act to consider the effectiveness and cost of a proposed benefit compared to alternative therapies. In making its recommendations the Committee, on the basis of community usage, recommends maximum quantities and repeats and may also recommend restrictions as to the indications where PBS subsidy is available. When recommending listings, the Committee provides advice to the Pharmaceutical Benefits Pricing Authority (PBPA) regarding comparison with alternatives or their cost effectiveness.

Products and services




We use cookies to ensure that we give you the best experience on our site. For more info

See our Cookie Privacy Policy Here